Sanofi-Synthelabo/Bristol Plan Avapro Heart Failure Program
Executive Summary
Sanofi-Synthelabo and co-marketing partner Bristol-Myers Squibb are discussing Phase III protocols in cardiac insufficiency for the angiotensin II inhibitor Avapro (irbesartan), Sanofi-Synthelabo COO Herve Guerin told an analysts meeting in London Sept. 2.
You may also be interested in...
Sanofi-Synthelabo Tirapazamine NDA Expected In 2003; ADSs Traded On NYSE
Sanofi-Synthelabo expects to file a tirapazamine NDA in late 2003 for the treatment of non-small cell lung cancer, the company said in a 1registration statement filed with the Securities & Exchange Commission
Sanofi-Synthelabo Tirapazamine NDA Expected In 2003; ADSs Traded On NYSE
Sanofi-Synthelabo expects to file a tirapazamine NDA in late 2003 for the treatment of non-small cell lung cancer, the company said in a 1registration statement filed with the Securities & Exchange Commission
Sanofi Prepares Pentasaccharide NDA For Nov. Following Favorable Phase III
Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.